Real-world evaluation of the positive predictive value and transmission burden of a novel implantable cardiac monitor with a remote reprogramming capability: insights from a single-center experience

Background Implantable cardiac monitors (ICMs) are widely used for long-term arrhythmia surveillance but are often limited by a high false-positive alert rate, increasing the workload for device clinics. The LUX-Dx™ ICM incorporates dual-stage detection algorithms and remote reprogramming features designed to improve diagnostic accuracy and workflow efficiency. Objective To assess the real-world performance of the LUX-Dx™ ICM across all detectable arrhythmias, evaluating positive predictive value (PPV), transmission burden, and the impact of remote reprogramming. Methods We retrospectively analyzed 133 consecutive patients who received a LUX-Dx™ ICM between July 2023 and October 2024 with follow-up data collected through June 2025. Device episodes and transmissions were reviewed over a median 13-month follow-up. PPV was calculated at both patient- and episode-levels. Changes in PPV before and after remote reprogramming were also assessed. Results A total of 55,064 episodes and 5,192 transmissions were recorded (4.0 episodes and 1.2 transmissions per patient-month). Overall patient-level PPV was 87% (110/126), highest for bradycardia (100%) and lowest for pauses (71%). Overall, 93 of 126 patients (74%) with adjudicated episodes had at least one false-positive detection during follow-up. Episode-level PPV was 82% (95% CI: 82−83). Remote reprogramming was performed in 34% of patients and was associated with a descriptive increase in episode-level PPV (from 77% to 87%). Review strategies focusing on the first, longest, or fastest episode per transmission yielded comparable PPVs. Conclusions In routine clinical practice, the LUX-Dx™ ICM demonstrated favorable positive predictive value. Remote reprogramming enabled individualized optimization of detection parameters, although its potential impact on detection performance requires further investigation.

Authors

Institutions

Publication Details

Journal
Frontiers in Cardiovascular Medicine
Published
2026-11-20
DOI
https://doi.org/10.3389/fcvm.2026.2008276
Primary Topic
Cardiac pacing and defibrillation studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Real-world evaluation of the positive predictive value and transmission burden of a novel implantable cardiac monitor with a remote reprogramming capability: insights from a single-center experience

Samir Fareh, Sergio Valsecchi, Mathieu Montoy, Monica Campari et al.
3 links
Frontiers in Cardiovascular Medicine
Cardiac pacing and defibrillation studies
article

Real-world evaluation of the positive predictive value and transmission burden of a novel implantable cardiac monitor with a remote reprogramming capability: insights from a single-center experience

Samir Fareh, Sergio Valsecchi, Mathieu Montoy, Monica Campari, Emilie Said, Paul Charles
article en

Abstract

Background Implantable cardiac monitors (ICMs) are widely used for long-term arrhythmia surveillance but are often limited by a high false-positive alert rate, increasing the workload for device clinics. The LUX-Dx™ ICM incorporates dual-stage detection algorithms and remote reprogramming features designed to improve diagnostic accuracy and workflow efficiency. Objective To assess the real-world performance of the LUX-Dx™ ICM across all detectable arrhythmias, evaluating positive predictive value (PPV), transmission burden, and the impact of remote reprogramming. Methods We retrospectively analyzed 133 consecutive patients who received a LUX-Dx™ ICM between July 2023 and October 2024 with follow-up data collected through June 2025. Device episodes and transmissions were reviewed over a median 13-month follow-up. PPV was calculated at both patient- and episode-levels. Changes in PPV before and after remote reprogramming were also assessed. Results A total of 55,064 episodes and 5,192 transmissions were recorded (4.0 episodes and 1.2 transmissions per patient-month). Overall patient-level PPV was 87% (110/126), highest for bradycardia (100%) and lowest for pauses (71%). Overall, 93 of 126 patients (74%) with adjudicated episodes had at least one false-positive detection during follow-up. Episode-level PPV was 82% (95% CI: 82−83). Remote reprogramming was performed in 34% of patients and was associated with a descriptive increase in episode-level PPV (from 77% to 87%). Review strategies focusing on the first, longest, or fastest episode per transmission yielded comparable PPVs. Conclusions In routine clinical practice, the LUX-Dx™ ICM demonstrated favorable positive predictive value. Remote reprogramming enabled individualized optimization of detection parameters, although its potential impact on detection performance requires further investigation.

Frontiers in Cardiovascular MedicineVol. 13
Boston Scientific (United States) (US), Hôpital de la Croix-Rousse (FR), Hospices Civils de Lyon (FR)
Good health and well-being
Cardiac pacing and defibrillation studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon